$CTXR
Citius Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000121390023039031 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.907M $5.958M $4.138M
YoY Change 21.82% 43.98% 56.76%
% of Gross Profit
Research & Development $3.765M $4.727M $3.452M
YoY Change -22.98% 36.92% 122.72%
% of Gross Profit
Depreciation & Amortization $630.00 $730.00 $730.00
YoY Change -13.7% 0.0%
% of Gross Profit
Operating Expenses $8.672M $10.69M $7.591M
YoY Change -2.74% 40.77% 81.16%
Operating Profit -$8.672M -$10.69M -$7.591M
YoY Change -2.74% 40.77%
Interest Expense $336.8K $303.3K $29.57K
YoY Change 925.63% -57.76%
% of Operating Profit
Other Income/Expense, Net $336.8K $303.3K
YoY Change
Pretax Income -$8.335M -$10.38M -$7.561M
YoY Change -5.96% 37.31% 83.52%
Income Tax $144.0K $144.0K
% Of Pretax Income
Net Earnings -$8.479M -$10.53M -$7.561M
YoY Change -4.34% 39.21% 83.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.07 -$0.05
Diluted Earnings Per Share -$0.06 -$0.07 -$51.77K
COMMON SHARES
Basic Shares Outstanding 158.9M shares 146.3M shares 146.0M shares
Diluted Shares Outstanding 153.8M shares 146.3M shares 146.0M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.28M $29.07M $55.76M
YoY Change -30.73% -47.87% -46.23%
Cash & Equivalents $33.28M $29.07M $55.76M
Short-Term Investments
Other Short-Term Assets $7.832M $5.836M $2.503M
YoY Change 180.7% 133.13% 92.55%
Inventory
Prepaid Expenses $7.832M $5.836M
Receivables
Other Receivables
Total Short-Term Assets $41.11M $34.90M $58.26M
YoY Change -19.12% -40.09% -44.51%
LONG-TERM ASSETS
Property, Plant & Equipment $2.010K $2.639K $741.8K
YoY Change -58.39% -99.64% -17.58%
Goodwill $9.347M $9.347M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $38.06K $38.06K $38.06K
YoY Change 0.0% 0.0%
Total Long-Term Assets $69.29M $69.34M $69.53M
YoY Change -0.27% -0.27% 134.1%
TOTAL ASSETS
Total Short-Term Assets $41.11M $34.90M $58.26M
Total Long-Term Assets $69.29M $69.34M $69.53M
Total Assets $110.4M $104.2M $127.8M
YoY Change -8.24% -18.43% -5.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.080M $2.726M $1.705M
YoY Change 82.17% 59.85% 55.01%
Accrued Expenses $892.9K $2.251M $2.317M
YoY Change -31.38% -2.85% 36.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.791M $6.210M $4.022M
YoY Change 29.81% 54.4% 34.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $320.0K $374.8K $582.3K
YoY Change -39.95% -35.63% -27.21%
Total Long-Term Liabilities $320.0K $374.8K $582.3K
YoY Change -39.95% -35.63% -41.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.791M $6.210M $4.022M
Total Long-Term Liabilities $320.0K $374.8K $582.3K
Total Liabilities $12.10M $12.43M $10.19M
YoY Change 21.29% 22.02% 7.27%
SHAREHOLDERS EQUITY
Retained Earnings -$152.3M -$143.8M
YoY Change 25.14%
Common Stock $158.9K $146.4K
YoY Change 8.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $97.70M $91.21M $117.6M
YoY Change
Total Liabilities & Shareholders Equity $110.4M $104.2M $127.8M
YoY Change -8.24% -18.43% -5.13%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.479M -$10.53M -$7.561M
YoY Change -4.34% 39.21% 83.41%
Depreciation, Depletion And Amortization $630.00 $730.00 $730.00
YoY Change -13.7% 0.0%
Cash From Operating Activities -$9.583M -$7.853M -$9.665M
YoY Change 24.25% -18.75% 125.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.80M 31.27K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.583M -7.853M -9.665M
Cash From Investing Activities
Cash From Financing Activities 13.80M 31.27K 0.000
Net Change In Cash 4.216M -7.822M -9.665M
YoY Change -154.67% -19.07% -109.72%
FREE CASH FLOW
Cash From Operating Activities -$9.583M -$7.853M -$9.665M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38174
dei Entity Registrant Name
EntityRegistrantName
Citius Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3425913
dei Entity Address Address Line1
EntityAddressAddressLine1
11 Commerce Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
First Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cranford
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07016
dei City Area Code
CityAreaCode
(908)
dei Local Phone Number
LocalPhoneNumber
967-6677
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CTXR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
158857798 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29065522 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41711690 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5835602 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2852580 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
34901124 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
44564270 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2639 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4100 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
552205 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646074 usd
CY2023Q1 us-gaap Deposits Assets
DepositsAssets
38062 usd
CY2022Q3 us-gaap Deposits Assets
DepositsAssets
38062 usd
CY2023Q1 ctxr In Process Research And Development
InProcessResearchAndDevelopment
59400000 usd
CY2022Q3 ctxr In Process Research And Development
InProcessResearchAndDevelopment
59400000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
9346796 usd
CY2022Q3 us-gaap Goodwill
Goodwill
9346796 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
68784858 usd
CY2022Q3 us-gaap Other Assets
OtherAssets
68784858 usd
CY2023Q1 us-gaap Assets
Assets
104240826 usd
CY2022Q3 us-gaap Assets
Assets
113999302 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2725593 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165378 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2250836 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1405394 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1025777 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1762251 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
207471 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196989 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6209677 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4530012 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5849800 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5561800 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
374831 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481245 usd
CY2023Q1 us-gaap Liabilities
Liabilities
12434308 usd
CY2022Q3 us-gaap Liabilities
Liabilities
10573057 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146357797 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146357797 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146211130 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146211130 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
146358 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
146211 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
234867917 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
232368121 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143808137 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129688467 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
91206138 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
102825865 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
600380 usd
CY2022Q3 us-gaap Minority Interest
MinorityInterest
600380 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
91806518 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
103426245 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104240826 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113999302 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4726855 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3452210 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8172370 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8910059 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4792850 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3117417 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7396137 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6014166 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1165595 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1020998 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2366676 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1925602 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
10685300 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7590625 usd
us-gaap Operating Expenses
OperatingExpenses
17935183 usd
us-gaap Operating Expenses
OperatingExpenses
16849827 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10685300 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7590625 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17935183 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16849827 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
303275 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
29571 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
517824 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
63553 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3585689 usd
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
303275 usd
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
29571 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
4103513 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
63553 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10382025 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7561054 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13831670 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16786274 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
144000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
288000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-10526025 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-7561054 usd
us-gaap Profit Loss
ProfitLoss
-14119670 usd
us-gaap Profit Loss
ProfitLoss
-16786274 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146251945 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146041852 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146231313 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146026847 shares
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
103426245 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1201081 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3593645 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
101033681 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
102000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31267 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1165595 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-10526025 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
91806518 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
132782733 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
95884 usd
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
904604 usd
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-9225220 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
124558001 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
178000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1020998 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-7561054 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
118195945 usd
us-gaap Profit Loss
ProfitLoss
-14119670 usd
us-gaap Profit Loss
ProfitLoss
-16786274 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2366676 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1925602 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
102000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
273884 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
93869 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
86619 usd
us-gaap Depreciation
Depreciation
1461 usd
us-gaap Depreciation
Depreciation
1461 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
288000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2983022 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-238295 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1560215 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
428033 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
845442 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
714669 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
736474 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
1112750 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-95932 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-86253 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12677435 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14316714 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31267 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31267 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12646168 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14316714 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41711690 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70072946 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29065522 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55756232 usd
CY2020Q3 us-gaap Shares Issued
SharesIssued
7500000 shares
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
19400000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
40000000 usd
CY2023Q1 us-gaap Goodwill Gross
GoodwillGross
9346796 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates </i>— Our accounting principles require our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
ctxr Negative Cash Flow Operations
NegativeCashFlowOperations
-12677435 usd
CY2023Q1 ctxr Working Capital
WorkingCapital
28700000 usd
CY2023Q2 ctxr Gross Proceeds
GrossProceeds
15000000 usd
CY2022Q2 us-gaap Cost Maintenance
CostMaintenance
90000 usd
CY2021Q2 us-gaap Cost Maintenance
CostMaintenance
90000 usd
us-gaap Royalty Expense
RoyaltyExpense
100000 usd
us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
25000 usd
ctxr Maximum Aggregate Annual Royalties
MaximumAggregateAnnualRoyalties
150000 usd
us-gaap Payments For Leasing Costs
PaymentsForLeasingCosts
1100000 usd
CY2023Q1 us-gaap Cost Maintenance
CostMaintenance
75000 usd
CY2022Q1 us-gaap Cost Maintenance
CostMaintenance
60000 usd
ctxr Milestone Payments
MilestonePayments
2100000 usd
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2034-01-02
ctxr Developmental Milestones Payment
DevelopmentalMilestonesPayment
51000000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.50 pure
us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK.
us-gaap Payments For Fees
PaymentsForFees
10000000 usd
CY2021Q4 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
50201 shares
CY2021Q4 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
95884 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
100000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
178000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
100000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
102000 usd
CY2023Q1 ctxr Option To Purchase Share Outstanding
OptionToPurchaseShareOutstanding
225000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
11810000 shares
ctxr Sharebased Compensations Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4
SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4
P10Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9400171 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
869509 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4075000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46667 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
34067 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13428504 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.83
ctxr Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
750721 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6179962 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M3D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
688121 usd
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.25
CY2022Q4 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
50000 shares
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.04
CY2023Q1 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
75000 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.42
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.97
CY2021Q4 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
375000 shares
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.04
CY2021Q4 ctxr Board Of Directors Granted Options To Purchase Shares
BoardOfDirectorsGrantedOptionsToPurchaseShares
200000 shares
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.87
CY2022Q1 ctxr Options To Purchase Shares
OptionsToPurchaseShares
300000 shares
CY2022Q1 ctxr Options To Purchase Shares
OptionsToPurchaseShares
300000 shares
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.44
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.49
ctxr Share Issued Price Per Share
ShareIssuedPricePerShare
1.69 shares
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1165595 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33333 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2366676 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66666 usd
CY2023Q1 ctxr Citius Stock Plans
CitiusStockPlans
6989559 usd
ctxr Weighted Average Period Term
WeightedAveragePeriodTerm
P1Y10M24D
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2000000 shares
ctxr Common Shares Outstanding
CommonSharesOutstanding
2000000 shares
CY2023Q1 ctxr Common Shares Outstanding
CommonSharesOutstanding
2000000 shares
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.24
CY2023Q1 us-gaap Shares Issued
SharesIssued
1417778 shares
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
116444 usd
CY2023Q1 ctxr Number Of Warrants Issued
NumberOfWarrantsIssued
38188998 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
13428504 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
11810000 shares
ctxr Warrants
Warrants
38188998 shares
ctxr Common Stock Reserved
CommonStockReserved
63427502 shares
ctxr Schedule Lease Expense
ScheduleLeaseExpense
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Lease cost</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">119,412</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">119,411</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">121,775</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">119,411</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Operating Lease Cost
OperatingLeaseCost
119412 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
119411 usd
us-gaap Variable Lease Cost
VariableLeaseCost
2363 usd
us-gaap Lease Cost
LeaseCost
121775 usd
us-gaap Lease Cost
LeaseCost
119411 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2023Q1 ctxr Operating Lease Future Minimum Payments Due Current
OperatingLeaseFutureMinimumPaymentsDueCurrent
122690 usd
CY2023Q1 ctxr Operating Lease Future Minimum Payments Due In Three Years
OperatingLeaseFutureMinimumPaymentsDueInThreeYears
249024 usd
CY2023Q1 ctxr Operating Lease Future Minimum Payments Due In Four Years
OperatingLeaseFutureMinimumPaymentsDueInFourYears
253883 usd
CY2023Q1 ctxr Operating Lease Future Minimum Payments Due In Five Years
OperatingLeaseFutureMinimumPaymentsDueInFiveYears
21460 usd
CY2023Q1 ctxr Operating Lease Future Minimum Payments Due
OperatingLeaseFutureMinimumPaymentsDue
647057 usd
CY2023Q1 ctxr Less Interest
LessInterest
64755 usd
CY2023Q1 ctxr Present Value Of Lease Liabilities
PresentValueOfLeaseLiabilities
582302 usd
ctxr Schedule Operating Leases Assets And Liabilities
ScheduleOperatingLeasesAssetsAndLiabilities
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Leases</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt">Operating</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">552,205</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">646,074</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease assets</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">552,205</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">646,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: center">Operating</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">207,471</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">374,831</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">481,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">582,302</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">678,234</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
552205 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646074 usd
CY2023Q1 ctxr Operating Lease Right Of Use Asset Total
OperatingLeaseRightOfUseAssetTotal
552205 usd
CY2022Q3 ctxr Operating Lease Right Of Use Asset Total
OperatingLeaseRightOfUseAssetTotal
646074 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
207471 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196989 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
374831 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
481245 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
582302 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
678234 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
25543 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
32792 usd
us-gaap Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax
DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax
3585689 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Variable Lease Cost
VariableLeaseCost
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001506251

Files In Submission

Name View Source Status
ctxr-20230331_def.xml Edgar Link unprocessable
0001213900-23-039031-index-headers.html Edgar Link pending
0001213900-23-039031-index.html Edgar Link pending
0001213900-23-039031.txt Edgar Link pending
0001213900-23-039031-xbrl.zip Edgar Link pending
ctxr-20230331.xsd Edgar Link pending
f10q0323ex10-1_citiuspharma.htm Edgar Link pending
f10q0323ex31-1_citiuspharma.htm Edgar Link pending
f10q0323ex31-2_citiuspharma.htm Edgar Link pending
f10q0323ex32-1_citiuspharma.htm Edgar Link pending
f10q0323_citiuspharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ctxr-20230331_cal.xml Edgar Link unprocessable
ctxr-20230331_lab.xml Edgar Link unprocessable
ctxr-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0323_citiuspharma_htm.xml Edgar Link completed